Our intent is to examine the predictive role of Charlson comorbidity index （CCI） on mortality of patients with type 2 diabetic nephropathy （DN）. Based on the CCI score, the severity of comorbidity was categorized ...Our intent is to examine the predictive role of Charlson comorbidity index （CCI） on mortality of patients with type 2 diabetic nephropathy （DN）. Based on the CCI score, the severity of comorbidity was categorized into three grades： mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; and severe, with CCI scores 〉5. Factors influencing mortality and differences between groups stratified by CCI were determined by logistical regression analysis and one-way analysis of variance （ANOVA）. The impact of CCI on mortality was assessed by the Kaplan- Meier analysis. A total of 533 patients with type 2 DN were enrolled in this study, all of them had comorbidity （CCI score 〉1）, and 44.7% （238/533） died. The mortality increased with CCI scores： 21.0% （50/238） patients with CCI scores of 1-2, 56.7% （135/238） patients with CCI scores of 3-4, and 22.3% （53/238） patients with CCI scores 〉5. Logistical regression analysis showed that CCI scores, hemoglobin, and serum albumin were the potential predictors of mortality （P〈0.05）. One-way ANOVA analysis showed that DN patients with higher CCI scores had lower levels of hemoglobulin, higher levels of serum creatinine, and higher mortality rates than those with lower CCI scores. The Kaplan-Meier curves showed that survival time decreased when the CCI scores and mortality rates went up. In con- clusion, CCI provides a simple, readily applicable, and valid method for classifying comorbidities and predicting the mortality of type 2 DN. An increased awareness of the potential comorbidities in type 2 DN patients may provide insights into this complicated disease and improve the outcomes by identifying and treating patients earlier and more effectively.展开更多
目的通过观察芪明颗粒对早期糖尿病肾病中医症候、生化指标、炎症因子及尿微量白蛋白的影响,明确与缬沙坦胶囊治疗效果的一致性及差异性。方法选入符合纳入标准的早期糖尿病肾病患者130例,采用简单数字表的随机方法分为治疗组65例和对照...目的通过观察芪明颗粒对早期糖尿病肾病中医症候、生化指标、炎症因子及尿微量白蛋白的影响,明确与缬沙坦胶囊治疗效果的一致性及差异性。方法选入符合纳入标准的早期糖尿病肾病患者130例,采用简单数字表的随机方法分为治疗组65例和对照组65例,2组均接受常规的治疗及护理,治疗组给芪明颗粒1袋/次,3次/d口服,对照组给予缬沙坦胶囊80 mg/次,1次/d口服,治疗16周后观察2组中医症候、生化指标、炎症因子及尿微量白蛋白的变化。结果治疗组与对照组临床疗效总有效率分别为92.31%、75.38%(P<0.05)。治疗前后2组在炎症因子方面均有所改善,但是对照组在hs-CRP、IL-6、IL-1β、TNF-α方面改善无统计学意义(P>0.05),治疗组在hs-CRP、IL-6、IL-1β、TNF-α、Cys-C方面与对照组比较有统计学意义(P<0.05),2组在血清β2-MG、24 h Um Alb方面比较,各组治疗前后有统计学意义(P<0.05),治疗后比较无统计学意义(P>0.05)。结论芪明颗粒在改善早期糖尿病肾病中医症候、炎症因子方面疗效显著,能明显改善血、尿微量白蛋白,延缓糖尿病肾病的发展。展开更多
基金Project supported by the Science and Technology Research Projects of Sichuan Province(No.2011SZ0215),China
文摘Our intent is to examine the predictive role of Charlson comorbidity index （CCI） on mortality of patients with type 2 diabetic nephropathy （DN）. Based on the CCI score, the severity of comorbidity was categorized into three grades： mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; and severe, with CCI scores 〉5. Factors influencing mortality and differences between groups stratified by CCI were determined by logistical regression analysis and one-way analysis of variance （ANOVA）. The impact of CCI on mortality was assessed by the Kaplan- Meier analysis. A total of 533 patients with type 2 DN were enrolled in this study, all of them had comorbidity （CCI score 〉1）, and 44.7% （238/533） died. The mortality increased with CCI scores： 21.0% （50/238） patients with CCI scores of 1-2, 56.7% （135/238） patients with CCI scores of 3-4, and 22.3% （53/238） patients with CCI scores 〉5. Logistical regression analysis showed that CCI scores, hemoglobin, and serum albumin were the potential predictors of mortality （P〈0.05）. One-way ANOVA analysis showed that DN patients with higher CCI scores had lower levels of hemoglobulin, higher levels of serum creatinine, and higher mortality rates than those with lower CCI scores. The Kaplan-Meier curves showed that survival time decreased when the CCI scores and mortality rates went up. In con- clusion, CCI provides a simple, readily applicable, and valid method for classifying comorbidities and predicting the mortality of type 2 DN. An increased awareness of the potential comorbidities in type 2 DN patients may provide insights into this complicated disease and improve the outcomes by identifying and treating patients earlier and more effectively.
文摘目的通过观察芪明颗粒对早期糖尿病肾病中医症候、生化指标、炎症因子及尿微量白蛋白的影响,明确与缬沙坦胶囊治疗效果的一致性及差异性。方法选入符合纳入标准的早期糖尿病肾病患者130例,采用简单数字表的随机方法分为治疗组65例和对照组65例,2组均接受常规的治疗及护理,治疗组给芪明颗粒1袋/次,3次/d口服,对照组给予缬沙坦胶囊80 mg/次,1次/d口服,治疗16周后观察2组中医症候、生化指标、炎症因子及尿微量白蛋白的变化。结果治疗组与对照组临床疗效总有效率分别为92.31%、75.38%(P<0.05)。治疗前后2组在炎症因子方面均有所改善,但是对照组在hs-CRP、IL-6、IL-1β、TNF-α方面改善无统计学意义(P>0.05),治疗组在hs-CRP、IL-6、IL-1β、TNF-α、Cys-C方面与对照组比较有统计学意义(P<0.05),2组在血清β2-MG、24 h Um Alb方面比较,各组治疗前后有统计学意义(P<0.05),治疗后比较无统计学意义(P>0.05)。结论芪明颗粒在改善早期糖尿病肾病中医症候、炎症因子方面疗效显著,能明显改善血、尿微量白蛋白,延缓糖尿病肾病的发展。
